Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.79 +6.9%	$6.31	$3.56 ▼ $12.92	$358.36M	0.48	253,883 shs	471,028 shs
IMUX Immunic	$0.95 +0.5%	$0.86	$0.56 ▼ $2.11	$93.22M	1.39	1.04 million shs	1.08 million shs
VIGL Vigil Neuroscience	$8.05	$8.02	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A
YMAB Y-mAbs Therapeutics	$8.53	$5.66	$3.55 ▼ $16.11	$387.59M	0.57	1.96 million shs	573,836 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	+6.93%	-0.88%	+1.65%	+73.21%	-43.08%
IMUX Immunic	+0.54%	+5.39%	-4.71%	+3.53%	-41.72%
VIGL Vigil Neuroscience	0.00%	0.00%	-0.25%	+2.03%	+121.15%
YMAB Y-mAbs Therapeutics	0.00%	+0.12%	+77.34%	+97.45%	-38.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.9074 of 5 stars	3.6	3.0	3.9	1.7	0.0
IMUX Immunic	2.5225 of 5 stars	3.6	1.0	2.3	2.5	0.6
VIGL Vigil Neuroscience	1.8509 of 5 stars	3.0	3.0	0.0	2.5	0.6
YMAB Y-mAbs Therapeutics	2.0547 of 5 stars	2.9	4.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.14	Buy	$29.00	327.10% Upside
IMUX Immunic	3.29	Buy	$7.50	689.47% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside
YMAB Y-mAbs Therapeutics	1.80	Reduce	$9.62	12.80% Upside

Current Analyst Ratings Breakdown

Latest IMUX, YMAB, VIGL, and ATXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ATXS Astria Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ATXS Astria Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $26.00
8/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/6/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$11.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$26.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underperform ➝ Neutral	$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$8.60

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$2.93 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.34 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A
YMAB Y-mAbs Therapeutics	$87.68M	4.42	N/A	N/A	$1.93 per share	4.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$2.01	N/A	N/A	N/A	N/A	-56.39%	-36.08%	N/A
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-461.46%	-217.16%	11/6/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	11/6/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	N/A

Latest IMUX, YMAB, VIGL, and ATXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	-$0.57	+$0.04	-$0.57	$16.00 million	N/A
8/8/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	-$0.07	+$0.20	-$0.07	$18.40 million	$19.52 million
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	14.89	14.89
IMUX Immunic	N/A	2.19	2.19
VIGL Vigil Neuroscience	N/A	2.97	2.97
YMAB Y-mAbs Therapeutics	N/A	4.00	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
IMUX Immunic	51.82%
VIGL Vigil Neuroscience	83.64%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
IMUX Immunic	4.60%
VIGL Vigil Neuroscience	18.01%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.44 million	53.90 million	Optionable
IMUX Immunic	70	98.65 million	94.11 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

IMUX, YMAB, VIGL, and ATXS Headlines

Recent News About These Companies

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 19, 2025 | globenewswire.com

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13, 2025 | insidermonkey.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 10, 2025 | marketbeat.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor Fitzgerald

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist Financial

August 8, 2025 | marketbeat.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

HC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

August 7, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call

August 7, 2025 | quiverquant.comQ

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

August 7, 2025 | globenewswire.com

HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)

August 7, 2025 | msn.com

SERB bets on rare cancer drug in $412 million deal for Y-mAbs

August 6, 2025 | thepharmaletter.comT

Jones Trading Downgrades Y-mAbs Therapeutics (YMAB)

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, YMAB, VIGL, and ATXS Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.79 +0.44 (+6.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.09 (+1.27%)

As of 08/22/2025 06:46 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Immunic NASDAQ:IMUX

$0.95 +0.01 (+0.54%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.96 +0.01 (+0.95%)

As of 08/22/2025 07:58 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$8.53 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.54 +0.01 (+0.06%)

As of 08/22/2025 06:24 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time